{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:15:25Z","timestamp":1793852125817,"version":"4.6.1"},"reference-count":75,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Anticoagulant-associated heavy menstrual bleeding (HMB) is an underrecognized but not uncommon problem in clinical practice. Premenopausal women should be advised of the potential effect of anticoagulant therapy on menstrual bleeding at the time of treatment initiation. Consequences of HMB should be assessed and treated on an ongoing basis. In the acute setting, the decision to withhold anticoagulants is based on an individual patient\u2019s risk of thrombosis and the severity of the bleeding. For women who require long-term anticoagulation, a levonorgestrel intrauterine system, tranexamic acid (during menstrual flow), high-dose progestin-only therapy, or combined hormonal contraceptives are effective for controlling HMB. The risk of thrombosis during anticoagulant therapy with these treatments is not well studied but is likely to be low. Selection of type of hormonal therapy is based on patient preference, other indications for and contraindications to therapy, adverse effect profile, and ongoing thrombotic risk factors. Women who do not respond to medical treatment or who do not wish to retain their fertility should be considered for surgical management.<\/jats:p>","DOI":"10.1182\/blood-2017-07-797423","type":"journal-article","created":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T16:08:57Z","timestamp":1509552537000},"page":"2603-2609","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":50,"title":["How I treat heavy menstrual bleeding associated with anticoagulants"],"prefix":"10.1182","volume":"130","author":[{"given":"Kochawan","family":"Boonyawat","sequence":"first","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, ON, Canada;"},{"name":"Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah H.","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology, The Ohio State University College of Medicine, The Ohio State University, Columbus, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon M.","family":"Bates","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, ON, Canada;"},{"name":"Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"15","key":"2019111908141400500_B1","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2014-07-590323","article-title":"The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis","volume":"124","author":"Chai-Adisaksopha","year":"2014","journal-title":"Blood"},{"key":"2019111908141400500_B2","author":"Ferreira"},{"issue":"7","key":"2019111908141400500_B3","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1055\/s-0036-1592304","article-title":"Direct oral anticoagulants and women","volume":"42","author":"Cohen","year":"2016","journal-title":"Semin Thromb Hemost"},{"key":"2019111908141400500_B4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.thromres.2017.03.013","article-title":"Oral contraception and menstrual bleeding during treatment of venous thromboembolism: Expert opinion versus current practice: Combined results of a systematic review, expert panel opinion and an international survey","volume":"153","author":"Klok","year":"2017","journal-title":"Thromb Res"},{"issue":"Suppl 1","key":"2019111908141400500_B5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0049-3848(17)30058-0","article-title":"Uterine bleeding during anticoagulation in women with venous thromboembolism","volume":"151","author":"Moustafa","year":"2017","journal-title":"Thromb Res"},{"issue":"3","key":"2019111908141400500_B6","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/humrep\/del478","article-title":"Can we achieve international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding?","volume":"22","author":"Fraser","year":"2007","journal-title":"Hum Reprod"},{"issue":"1","key":"2019111908141400500_B7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijgo.2010.11.011","article-title":"FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age","volume":"113","author":"Munro","year":"2011","journal-title":"Int J Gynaecol Obstet"},{"key":"2019111908141400500_B8"},{"issue":"5","key":"2019111908141400500_B9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1055\/s-0031-1287662","article-title":"The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding","volume":"29","author":"Fraser","year":"2011","journal-title":"Semin Reprod Med"},{"issue":"5","key":"2019111908141400500_B10","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/0002-9378(90)90031-2","article-title":"Measured menstrual blood loss in women with a bleeding disorder or using oral anticoagulant therapy","volume":"162","author":"van Eijkeren","year":"1990","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"2019111908141400500_B11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.contraception.2010.12.011","article-title":"Menstrual problems and contraception in women of reproductive age receiving oral anticoagulation","volume":"84","author":"Huq","year":"2011","journal-title":"Contraception"},{"issue":"12","key":"2019111908141400500_B12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1440-1754.2011.02101.x","article-title":"Effect of warfarin on menstruation and menstrual management of the adolescent on warfarin","volume":"47","author":"Peake","year":"2011","journal-title":"J Paediatr Child Health"},{"key":"2019111908141400500_B13","year":"2011"},{"issue":"1","key":"2019111908141400500_B14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11239-006-0003-7","article-title":"Menorrhagia and minor bleeding symptoms in women on oral anticoagulation","volume":"24","author":"Sj\u00e4lander","year":"2007","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"2019111908141400500_B15","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/bjh.13583","article-title":"Heavy menstrual bleeding on rivaroxaban","volume":"173","author":"Ferreira","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111908141400500_B16","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.thromres.2015.07.030","article-title":"Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists","volume":"136","author":"De Crem","year":"2015","journal-title":"Thromb Res"},{"key":"2019111908141400500_B17","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.14003","article-title":"Heavy menstrual bleeding on Rivaroxaban - Comparison with Apixaban","author":"Myers","year":"2017","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111908141400500_B18","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2015-08-665927","article-title":"Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use","volume":"127","author":"Martinelli","year":"2016","journal-title":"Blood"},{"key":"2019111908141400500_B19","author":"Boonyawat"},{"key":"2019111908141400500_B20","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2016.09.007","article-title":"Impact of gender on safety and efficacy of Rivaroxaban in adolescents & young adults with venous thromboembolism","author":"Krause","year":"2016"},{"issue":"4","key":"2019111908141400500_B21","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1160\/TH16-11-0874","article-title":"Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin","volume":"117","author":"Brekelmans","year":"2017","journal-title":"Thromb Haemost"},{"issue":"10","key":"2019111908141400500_B22","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1016\/S2352-3026(16)30111-9","article-title":"Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series","volume":"3","author":"Beyer-Westendorf","year":"2016","journal-title":"Lancet Haematol"},{"issue":"22","key":"2019111908141400500_B23","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.140.140","article-title":"Dabigatran is associated with a significantly lower risk of abnormal uterine bleeding than warfarin in female patients of childbearing age with venous thromboembolism [abstract]","volume":"128","author":"Ferreira","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2019111908141400500_B24","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1160\/TH15-11-0902","article-title":"Vaginal bleeding and heavy menstrual bleeding during direct oral anti-Xa inhibitor therapy","volume":"115","author":"Beyer-Westendorf","year":"2016","journal-title":"Thromb Haemost"},{"issue":"5","key":"2019111908141400500_B25","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.ajog.2003.11.015","article-title":"Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data","volume":"190","author":"Warner","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"2019111908141400500_B26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2007.08.070","article-title":"Development of a screening tool for identifying women with menorrhagia for hemostatic evaluation","author":"Philipp","year":"2008"},{"issue":"2","key":"2019111908141400500_B27","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/00365516409060511","article-title":"Determination of menstrual blood loss","volume":"16","author":"Hallberg","year":"1964","journal-title":"Scand J Clin Lab Invest"},{"issue":"8","key":"2019111908141400500_B28","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1471-0528.1990.tb16249.x","article-title":"Assessment of menstrual blood loss using a pictorial chart","volume":"97","author":"Higham","year":"1990","journal-title":"Br J Obstet Gynaecol"},{"issue":"3","key":"2019111908141400500_B29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10397-015-0893-5","article-title":"Pictorial blood loss assessment chart for quantification of menstrual blood loss: a systematic review","volume":"12","author":"El-Nashar","year":"2015","journal-title":"Gynecol Surg"},{"issue":"5","key":"2019111908141400500_B30","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/1471-0528.13273","article-title":"The menstrual bleeding questionnaire: development and validation of a comprehensive patient-reported outcome instrument for heavy menstrual bleeding","volume":"122","author":"Matteson","year":"2015","journal-title":"BJOG"},{"issue":"1","key":"2019111908141400500_B31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1472-6874-14-71","article-title":"A simple and feasible questionnaire to estimate menstrual blood loss: relationship with hematological and gynecological parameters in young women","volume":"14","author":"Toxqui","year":"2014","journal-title":"BMC Womens Health"},{"issue":"4","key":"2019111908141400500_B32","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S1701-2163(16)34151-2","article-title":"A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia","volume":"31","author":"Endrikat","year":"2009","journal-title":"J Obstet Gynaecol Can"},{"issue":"4","key":"2019111908141400500_B33","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/AOG.0b013e3182118ac3","article-title":"Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial","volume":"117","author":"Jensen","year":"2011","journal-title":"Obstet Gynecol"},{"issue":"10","key":"2019111908141400500_B34","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1093\/humrep\/der224","article-title":"Effective treatment of heavy and\/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial","volume":"26","author":"Fraser","year":"2011","journal-title":"Hum Reprod"},{"issue":"1","key":"2019111908141400500_B35","first-page":"CD001016","article-title":"Cyclical progestogens for heavy menstrual bleeding","author":"Lethaby","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2019111908141400500_B36","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1471-0528.1998.tb10172.x","article-title":"Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia","volume":"105","author":"Irvine","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"issue":"2","key":"2019111908141400500_B37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.contraception.2009.02.008","article-title":"Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons","volume":"80","author":"Hubacher","year":"2009","journal-title":"Contraception"},{"issue":"1","key":"2019111908141400500_B38","first-page":"57","article-title":"Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers","volume":"35","author":"K\u00fc\u00e7\u00fck","year":"2008","journal-title":"Clin Exp Obstet Gynecol"},{"issue":"12","key":"2019111908141400500_B39","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1177\/0961203306071706","article-title":"Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil)","volume":"15","author":"Pisoni","year":"2006","journal-title":"Lupus"},{"issue":"4","key":"2019111908141400500_B40","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.ajog.2005.05.002","article-title":"The use of the levonorgestrel-releasing intrauterine system in the management of menorrhagia in women with hemostatic disorders","volume":"193","author":"Schaedel","year":"2005","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"2019111908141400500_B41","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.fertnstert.2007.07.1315","article-title":"Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders","volume":"90","author":"Lukes","year":"2008","journal-title":"Fertil Steril"},{"issue":"4","key":"2019111908141400500_B42","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jmig.2009.04.018","article-title":"The levonorgestrel intrauterine system is an effective treatment in women with abnormal uterine bleeding and anticoagulant therapy","volume":"16","author":"Vilos","year":"2009","journal-title":"J Minim Invasive Gynecol"},{"issue":"2","key":"2019111908141400500_B43","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.contraception.2009.02.007","article-title":"The effect of levonorgestrel-releasing intrauterine device on menorrhagia in women taking anticoagulant medication after cardiac valve replacement","volume":"80","author":"Kilic","year":"2009","journal-title":"Contraception"},{"issue":"4","key":"2019111908141400500_B44","first-page":"CD002126","article-title":"Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding","author":"Lethaby","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2019111908141400500_B45"},{"issue":"4","key":"2019111908141400500_B46","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1538-7836.2012.04662.x","article-title":"Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH","volume":"10","author":"Baglin","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111908141400500_B47","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00404-014-3394-2","article-title":"Conservative management of corpus luteum haemorrhage in patients on anticoagulation: a report of three cases and review of literature","volume":"291","author":"Gupta","year":"2015","journal-title":"Arch Gynecol Obstet"},{"key":"2019111908141400500_B48","doi-asserted-by":"crossref","first-page":"f5298","DOI":"10.1136\/bmj.f5298","article-title":"Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis","volume":"347","author":"Stegeman","year":"2013","journal-title":"BMJ"},{"key":"2019111908141400500_B49","doi-asserted-by":"crossref","first-page":"e2990","DOI":"10.1136\/bmj.e2990","article-title":"Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10","volume":"344","author":"Lidegaard","year":"2012","journal-title":"BMJ"},{"issue":"1","key":"2019111908141400500_B50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.thromres.2010.01.045","article-title":"Mechanisms of estrogen-induced venous thromboembolism","volume":"126","author":"Tchaikovski","year":"2010","journal-title":"Thromb Res"},{"key":"2019111908141400500_B51","doi-asserted-by":"crossref","first-page":"d6423","DOI":"10.1136\/bmj.d6423","article-title":"Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9","volume":"343","author":"Lidegaard","year":"2011","journal-title":"BMJ"},{"key":"2019111908141400500_B52","doi-asserted-by":"crossref","first-page":"e4944","DOI":"10.1136\/bmj.e4944","article-title":"Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis","volume":"345","author":"Mantha","year":"2012","journal-title":"BMJ"},{"issue":"9190","key":"2019111908141400500_B53","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/S0140-6736(99)03132-3","article-title":"Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications","volume":"354","author":"Poulter","year":"1999","journal-title":"Lancet"},{"issue":"9190","key":"2019111908141400500_B54","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/S0140-6736(99)04394-9","article-title":"Risk of idiopathic venous thromboembolism in users of progestagens alone","volume":"354","author":"Vasilakis","year":"1999","journal-title":"Lancet"},{"issue":"3","key":"2019111908141400500_B55","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/AOG.0000000000000411","article-title":"Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes","volume":"124","author":"Bergendal","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"11","key":"2019111908141400500_B56","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1161\/ATVBAHA.110.211482","article-title":"The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device","volume":"30","author":"van Hylckama Vlieg","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"2019111908141400500_B57","first-page":"CD000249","article-title":"Antifibrinolytics for heavy menstrual bleeding","author":"Lethaby","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2019111908141400500_B58","first-page":"714","article-title":"No increased risk of venous thrombosis in women taking tranexamic acid","volume":"86","author":"Berntorp","year":"2001","journal-title":"Thromb Haemost"},{"issue":"1","key":"2019111908141400500_B59","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1471-0528.2008.01926.x","article-title":"The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database","volume":"116","author":"Sundstr\u00f6m","year":"2009","journal-title":"BJOG"},{"issue":"9734","key":"2019111908141400500_B60","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(10)60835-5","article-title":"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial","volume":"376","author":"Shakur","year":"2010","journal-title":"Lancet"},{"key":"2019111908141400500_B61","doi-asserted-by":"crossref","first-page":"e3054","DOI":"10.1136\/bmj.e3054","article-title":"Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.","volume":"344","author":"Ker","year":"2012","journal-title":"BMJ"},{"key":"2019111908141400500_B62","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1756-0500-6-184","article-title":"Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis","volume":"6","author":"Gandhi","year":"2013","journal-title":"BMC Res Notes"},{"issue":"1","key":"2019111908141400500_B63","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/aogs.12798","article-title":"Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials","volume":"95","author":"Simonazzi","year":"2016","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"8","key":"2019111908141400500_B64","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"13","key":"2019111908141400500_B65","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111908141400500_B66","first-page":"652","article-title":"[Hysteroscopic endometrium ablation in \u201chigh-risk\u201d situations and in hemorrhagic diathesis]","volume":"117","author":"Wallwiener","year":"1995","journal-title":"Zentralbl Gynakol"},{"issue":"1","key":"2019111908141400500_B67","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0301-2115(97)00232-7","article-title":"Endometrial resectoscopic ablation in patients with menometrorrhagia as a side effect of anticoagulant therapy","volume":"77","author":"Goldenberg","year":"1998","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"12","key":"2019111908141400500_B68","doi-asserted-by":"crossref","first-page":"e16699","DOI":"10.5812\/ircmj.16699","article-title":"Uterine artery embolization for treatment of symptomatic fibroids: a review of the evidence","volume":"15","author":"Firouznia","year":"2013","journal-title":"Iran Red Crescent Med J"},{"issue":"8","key":"2019111908141400500_B69","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/0002-9378(83)90237-5","article-title":"Uterine tamponade for the control of acute uterine bleeding","volume":"147","author":"Goldrath","year":"1983","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"2019111908141400500_B70","doi-asserted-by":"crossref","first-page":"2769.e13","DOI":"10.1016\/j.fertnstert.2010.04.058","article-title":"Intrauterine balloon tamponade as a treatment for immune thrombocytopenic purpura-induced severe uterine bleeding","volume":"94","author":"Hamani","year":"2010","journal-title":"Fertil Steril"},{"issue":"4","key":"2019111908141400500_B71","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/01.AOG.0000428646.67925.9a","article-title":"ACOG committee opinion no. 557: Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women","volume":"121","author":"American College of Obstetricians and Gynecologists","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"5987","key":"2019111908141400500_B72","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/bmj.4.5987.17","article-title":"Aminocaproic acid and menstrual loss in women using intrauterine devices","volume":"4","author":"Kasonde","year":"1975","journal-title":"Br Med J"},{"issue":"5","key":"2019111908141400500_B73","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","article-title":"Ulipristal acetate versus placebo for fibroid treatment before surgery","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111908141400500_B74","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","article-title":"Ulipristal acetate versus leuprolide acetate for uterine fibroids","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111908141400500_B75","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/whe.15.100","article-title":"Medical management of heavy menstrual bleeding","volume":"12","author":"Maybin","year":"2016","journal-title":"Womens Health (Lond)"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/24\/2603\/1403927\/blood797423.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/24\/2603\/1403927\/blood797423.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T08:15:06Z","timestamp":1574151306000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/24\/2603\/36855\/How-I-treat-heavy-menstrual-bleeding-associated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,14]]},"references-count":75,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2017,12,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-07-797423","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,14]]}}}